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Introduction
The treatment of multiple myeloma (MM) has greatly improved 
in recent years with FDA approval of agents in the immunomod-
ulatory imide drug (IMiD) and proteasome inhibitor drug classes. 
Nevertheless, myeloma remains incurable, and patients inevita-
bly develop treatment-refractory disease. Furthermore, high-risk 
cytogenetic subgroups, including those with deletion of chro-
mosome 17p or gain of chromosome 1q21, progress more rapidly 
through approved agents and have shortened overall survival (1, 
2). Therefore, patients with relapsed/refractory (R/R) disease or 
with poor cytogenetic profiles are in dire need of novel therapies.
Antibody-based therapies have potential to fill this clinical 
need. Naked antibodies have recently shown increased promise 
with demonstration of single-agent activities of the anti-CD38 
antibodies daratumumab and SAR650984 (3, 4). In addition, the 
anti–signaling lymphocyte activation molecule family member 
7 (anti-SLAMF7) antibody elotuzumab was recently shown to 
improve outcome in combination with lenalidomide and dexa-
methasone in a randomized phase III trial (5). Antibody-drug 
conjugates (ADCs) have potential to further improve on the clin-
ical efficacy of naked antibodies via targeted delivery of high-
ly cytotoxic payloads directly to malignant plasma cells (6–8). 
ADCs have recently seen proof-of-concept clinical success in 
Hodgkin lymphoma (brentuximab vedotin) and human epider-
mal growth factor receptor 2–positive (HER2-positive) breast 
cancer (ado-trastuzumab emtansine) (9, 10). Because of the 
considerable potential for clinical benefit, novel ADCs should be 
evaluated in MM (11).
Our research objective is to identify a novel ADC for MM 
treatment, with an emphasis toward patients with R/R disease. 
We previously developed a novel antibody discovery method 
based on a phage antibody library selection on tissue using laser 
capture microdissection (12). By this method, antibodies were 
identified that bind to tumor cells residing in their natural micro-
environment (12). The platform was pioneered on prostate cancer 
tissue. One novel antibody that showed excellent in vivo target-
ing properties (13) has been identified to target the CD46 antigen 
(also known as membrane cofactor protein, MCP; Y. Su and B. Liu, 
unpublished observations). CD46 is a multifunctional protein that 
has a role in complement inhibition, which may explain its overex-
pression on malignant cells (14), and cellular entry by pathogens 
including measles virus (15, 16). The latter quality has led to CD46 
targeting in viral immunotherapy with the Edmonston strain of 
measles virus (17). In normal tissue, CD46 appears to have a low 
level of expression outside placenta and prostate (14).
The CD46 gene is located on the long arm of chromosome 1 
(1q32.2), 50 Mbp from a clinically used FISH probe that may pro-
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Results
CD46 antigen is highly expressed in myeloma cell lines. To evaluate 
whether CD46 was overexpressed in MM, we studied its cell sur-
face expression by FACS on cell lines. CD46 was highly expressed 
on the cell surface of all MM cell lines tested (Figure 1A and Supple-
mental Figure 1; supplemental material available online with this 
article; doi:10.1172/JCI85856DS1). We next sought to quantify the 
CD46 antigen number per cell (referred to henceforth as antigen 
density), using methods described previously (25). The mean anti-
gen density on MM cell lines RPMI8226 and MM1.S ranged from 
454,668 to 470,991 for CD46, compared with 314,953 to 344,865 
for CD38, a commonly used marker for MM (Figure 1B). It has 
previously been reported that extracellular CD46 antigen is shed 
from the cell surface of solid tumor cell lines (26). To assess wheth-
er MM cells shed CD46 antigen, we conducted Western blotting 
of cell lysates and supernatants from RPMI8226 cells. In either the 
presence or the absence of CD46 antibody stimulation, we found 
no appreciable shedding of CD46 antigen from MM cells into the 
culture supernatant (Supplemental Figure 2).
CD46 is upregulated in the context of the BM microenvironment. 
Myeloma is a disease in which the BM microenvironment promotes 
MM cell survival and chemotherapy resistance (27). The majority of 
MM patients have disease that is primarily localized to the BM. To 
assess whether the CD46 expression level in MM cells is impacted 
by this microenvironment, MM1.S cells were cocultured with the 
BM stromal cell line HS5. Analysis of mRNA expression by RNA 
sequencing (RNA-seq) showed the CD46 mRNA level increased in 
MM1.S when cocultured with HS5, compared with monocultures 
vide a surrogate marker for CD46. FISH is used clinically in MM 
for risk stratification, and amplification of 1q occurs commonly 
in MM (1, 18–20). Amplification of 1q21 (amp1q21) is considered 
a high-risk feature that becomes more prevalent at relapse (1, 2, 
21). A recent report also suggests that amp1q21 remains a poor 
prognostic factor in the era of current protease inhibitor and IMiD 
therapies (22). Thus, antibody-based targeting of cell surface anti-
gens such as CD46 that undergo genomic copy number gain on 
chromosome 1q is an attractive possibility in myeloma.
Our selection method preferentially identifies human mono-
clonal antibodies that are internalized via macropinocytosis, a 
tumor-selective pathway for cellular entry (23), and thus are well 
suited for ADC development (24). Therefore, we used these anti-
bodies to develop a novel anti-CD46 ADC with the microtubule 
inhibitor monomethyl auristatin F (MMAF) (hereafter referred 
to as CD46-ADC). Herein we describe the preclinical character-
ization of CD46-ADC in MM using cell lines, orthometastatic 
xenograft models, and patient samples. We found high CD46 
expression on MM cell lines and patient samples, and the expres-
sion level is further upregulated upon coculture with bone mar-
row (BM) stromal cells. CD46-ADC showed potent and specific 
myeloma cell killing activity in vitro and in vivo and on primary 
MM cells ex vivo. Thus, CD46-ADC has potential to be an effica-
cious treatment for MM. Finally, we evaluated the hypothesis that 
patients with disease demonstrating amp1q21 by FISH also coam-
plify the CD46 gene and upregulate antigen expression on the MM 
cell surface. The results support the use of 1q21 FISH as a biomark-
er for translation of CD46-targeting agents for use in MM.
Figure 1. CD46 is highly expressed on MM cells and is 
further increased in the setting of BM microenvironment. 
(A) CD46 expression in INA-6, RPMI8226, MM1.S, and MM1.R 
measured by FACS (solid lines), compared with nonbinding 
control (Ctrl = dashed lines, representative data, n = 3). (B) 
CD46 antigen density estimation compared with CD38 on 
RPMI8226 and MM1.S (data represent mean ± SEM, n = 3). 
(C) Coculture of MM1.S with HS5 BM stromal cells increases 
the expression of CD46 mRNA (n = 2). RPKM, reads per 
kilobase of transcript per million mapped reads. (D) CD46 
and CD38 antigen densities in RPMI8226 and MM1.S, 
incubated with or without HS5-conditioned media (CM) for 
3 days (data represent mean ± SEM, n = 3–5). Two-tailed 
Student’s t test, *P < 0.05, **P < 0.01.
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Generation of anti-CD46 antibody and internalization by myelo-
ma cells. We generated a panel of human monoclonal antibodies 
binding to domains 1 and 2 of human CD46 by phage and yeast 
antibody display (28) and identified a lead antibody, 23AG2, 
that binds to the target antigen specifically with high affinity. 
The equilibrium dissociation constant (KD) of the antibody on a 
recombinant human CD46 protein fragment was 2.99 nM on the 
BLItz system (Supplemental Figure 3). Measured on living MM 
cells, 23AG2 KD values were 1.19 nM for RPMI8226 and 2.24 nM 
for MM1.S, respectively (Supplemental Figure 4). To determine 
whether the anti-CD46 antibody (23AG2) is internalized by MM 
cells, we incubated the antibody with MM1.R, analyzed inter-
(Figure 1C). To assess whether this observation could be general-
ized to other MM cell lines and coculture conditions, MM1.S and 
MM1.R were incubated with HS5-conditioned media and ana-
lyzed by FACS for CD46. For comparison, CD38 was also studied 
in parallel. MM1.S and MM1.R cells showed upregulation of CD46 
when cultured with HS5-conditioned media (P = 0.0031 and 0.02, 
respectively), suggesting that a factor from BM stromal cells may 
increase CD46 expression by MM cells (Figure 1D). In contrast, 
CD38 showed a variable response upon incubation of MM1.S and 
MM1.R cells with stromal cell–conditioned media (P = 0.15 and 0.8, 
respectively) (Figure 1D). The nature of the factor(s) and whether it 
is BM specific remains to be determined.
Figure 2. Potent and selective activity of CD46-ADC on MM cells compared with BM stromal cells, with potentiation of ADC effect in the context of 
MM-stromal interactions. (A) Confocal immunocytochemistry of MM1.R after 4 (left) and 18 (right) hours of incubation with anti-CD46 antibody (red). Late 
lysosomes shown with anti-LAMP1 antibody (green), and partial colocalization shown in merged panel (yellow). (B) Dose response for CD46-ADC inhibition 
of viability of MM cells compared with HS5 and BM61 BM stromal cells after 96-hour incubation (n = 3). NR: EC50 not reached due to lack of killing at the 
highest concentration tested. (C) Lack of effect of nonbinding control ADC until approximately 100 nM (n = 3). (D) Annexin V and PI staining of MM cell line 
INA-6 for 0–10 nM CD46-ADC, with apoptosis and death by 48 hours (representative data, n = 3). (E) Sensitivity of MM1.S cell line to CD46-ADC is increased 
in the presence of HS5, BM61, or HS27A BM stromal cells. EC50 was 2.25 nM on MM1.S alone and 0.77 nM, 0.92 nM, and 1.05 nM for MM1.S in the presence 
of HS5, HS27A, and BM61, respectively (data represent mean ± SEM, n = 3).
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tions tested (up to 150 nM, no EC50 estimated) (Figure 2B). Isotype 
control ADC constructed with a nonbinding antibody showed lit-
tle to no effect on MM cell line proliferation at concentrations up 
to 67 nM (Figure 2C). The level of both CD46 transcript and cell 
surface expression measured by FACS correlated inversely with 
the EC50 of CD46-ADC (Supplemental Figure 7, A and B), suggest-
ing that surface expression is a reasonable surrogate for potency. 
The induction of apoptosis and death was detectable in MM cells 
tested for annexin V and propidium iodide (PI) after 48 hours of 
ADC treatment (Figure 2D). Next, we examined the effect of BM 
microenvironment interactions on the efficacy of CD46-ADC. 
Cocultures of MM1.S cells with BM61, HS5, or HS27A BM stromal 
cells enhanced the potency of CD46-ADC (Figure 2E), consistent 
with our observations of increased CD46 expression in coculture 
and correlation of potency to CD46 levels described above.
We next sought to validate that CD46-ADC cytotoxicity is 
dependent on binding to CD46 for specific tumor cell killing. First, 
competitive cell binding of the anti-CD46 antibody was measured 
and detected in the presence of increasing amounts of the recom-
binant CD46-Fc fusion protein (Supplemental Figure 8A). In addi-
tion, the CD46-Fc blocked the cytotoxic effect of CD46-ADC 
(Supplemental Figure 8B). Next, the effect of CD46 knockdown 
on myeloma cell cytotoxicity of CD46-ADC was tested. The MM 
cell line H929 was infected with lentivirus coexpressing green 
fluorescent protein (GFP) and shRNA against CD46. By quantita-
nalization using confocal microscopy, and studied colocalization 
with lysosomal-associated membrane protein 1 (LAMP1). CD46 
antibody was internalized and colocalized with LAMP1 (Figure 
2A), indicating subcellular localization that is well suited for ADC 
delivery. This was also performed on RPMI8226 cells with similar 
results (data not shown).
Anti–CD46-ADC has potent and selective cytotoxicity against 
myeloma cell lines. To provide an initial assessment of CD46 as 
a suitable ADC target, we conjugated our antibody to a mem-
brane-impermeant plant toxin (saporin) to form an immunotox-
in and evaluated its effect on RPMI8226 cells. The immunotoxin 
showed strong inhibition of cell proliferation with EC50 in the pico-
molar range, with no effect observed from toxin alone (Supple-
mental Figure 5). We next covalently conjugated the MMAF to our 
anti-CD46 antibody via a lysosomal protease–sensitive valine- 
citrulline linker (8, 29). HPLC analysis with hydrophobic interac-
tion chromatography of the final conjugate showed an average drug 
per antibody of 3.3 (Supplemental Figure 6). We tested the CD46-
ADC on the RMPI8226 cell line and found that it also potently 
killed MM cells with EC50 in the picomolar range (Figure 2B).
On the panel of MM cell lines, CD46-ADC showed an EC50 
range of 150 pM to 5 nM (Figure 2B). On BM stromal cells, CD46-
ADC had an EC50 greater than 100 nM for patient-derived BM61 
cells (generated via culture of CD138-negative BM mononuclear 
cells) and essentially no effect on HS5 cells across all concentra-
Figure 3. In vivo CD46-ADC antimyeloma activity in the RPMI8226-Luc disseminated xenograft model. (A) Study treatment scheme. RPMI8226-Luc  
cells were injected i.v. and established for 10 days. Starting on the tenth day (treatment day 1), a total of 4 injections of PBS, control nonbinding ADC  
(5 mg/kg), naked CD46 antibody (5 mg/kg), CD46-ADC (5 mg/kg), or bortezomib (1 mg/kg) were given twice per week (n = 5 mice per group). (B) Disease 
was monitored by bioluminescence imaging (BLI) (top views, dorsal; bottom views, ventral). BLI measurement in photons per second per cm2 per steradian 
(p/s/cm2/sr) was translated to color to indicate disease activity in the mice by the legend shown at far right. Tx, treatment; mAb, naked antibody. (C) 
Kaplan-Meier survival curves of NSG xenografts transplanted with RPMI-Luc and treated with CD46-ADC or controls.
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to reverse growth (Figure 3B). It should be noted that this borte-
zomib schedule was chosen for comparison with the ADC, not to 
simulate clinical use, which would be continuous. The survival of 
mice treated with CD46-ADC was significantly improved over that 
of control groups (hazard ratio [HR] = 0.151 between control-ADC 
and CD46-ADC; P = 0.004), with most of the treated animals liv-
ing until study was discontinued at day 200 (Figure 3C).
Next, a luciferase reporter–bearing MM1.S cell line was used 
in a second xenograft model of orthometastatic MM. Two differ-
ent ADC doses and a single-dose regimen were investigated (Fig-
ure 4). Mice were treated once every 3–4 days at either 4 mg/kg or 
0.8 mg/kg for a total of 4 injections. A third group was treated with 
a single dose of 4 mg/kg. Tumor burden continually increased in 
the control groups treated with vehicle and control ADC (Figure 
4A). Naked CD46 antibody delayed increase in bioluminescence, 
but mice succumbed by day 53. The single dose showed elimina-
tion of bioluminescence by day 36, but all mice relapsed and suc-
cumbed by day 139 (Figure 4C). The 0.8-mg/kg (4-dose) regimen 
eliminated bioluminescence through day 43, but all succumbed 
tive FACS analysis, CD46 antigen density was knocked down by 
82% from 146,647 in uninfected (GFP-negative) cells to 25,847 
in GFP-positive cells (Supplemental Figure 8C). The knockdown 
of CD46 reduced the induction of cell death by CD46-ADC com-
pared with scrambled shRNA control (Supplemental Figure 8D), 
providing additional evidence that cytotoxicity of CD46-ADC 
is dependent on CD46 expression. In summary, CD46-ADC is 
potent and specifically cytotoxic to MM cells in vitro, and is fur-
ther potentiated in models of the BM microenvironment.
Anti–CD46-ADC potently eliminates MM cell line xenografts in 
vivo. RPMI8226 cells expressing firefly luciferase (RPMI8226-
Luc) were used to establish an orthometastatic xenograft mod-
el in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice, as previously 
described (30). A total of 4 injections of CD46-ADC at 5 mg/kg 
were given once every 3–4 days. CD46-ADC resulted in near-com-
plete elimination of myeloma cell bioluminescent signal, whereas 
controls (vehicle, nonbinding ADC, naked antibody) did not (Fig-
ure 3, A and B). A comparison group was treated with bortezomib, 
which delayed increase in the bioluminescence activity but failed 
Figure 4. Dose- and schedule-dependent in vivo activity of CD46-ADC in a disseminated MM xenograft model with MM1.S cell line. (A) Study treatment 
scheme. MM1.S-Luc cells were injected and established for 10 days. Starting on day 11 (treatment day 1), a total of 4 injections were given twice a week 
at the concentrations shown for all groups, except for the single-dose group. For each group, n= 5 mice per group. (B) BLI rapidly increased in negative 
control groups, but decreased to undetectable levels with all CD46-ADC treatment regimens (top views, dorsal; bottom views, ventral). Relapse of disease 
activity was observed progressively at single-dose 4-mg/kg and low-dose 0.8-mg/kg groups. No detectable BLI signal and no relapse after treatment was 
observed for the 4-mg/kg, 4-dose schedule, suggesting complete elimination of MM1.S xenografts in vivo. BLI in photons per second per cm2 per steradian 
(p/s/cm2/sr) was translated to color to indicate disease activity by the legend shown at far right. Tx, treatment; mAb, naked antibody. (C) Kaplan-Meier 
survival curves of NSG xenografts transplanted with MM1.S-Luc and treated with varying dose levels of CD46-ADC.
Downloaded from http://www.jci.org on January  4, 2017.   https://doi.org/10.1172/JCI85856
The Journal of Clinical Investigation   R E S E A R C H  A R T I C L E
4 6 4 5jci.org   Volume 126   Number 12   December 2016
by day 173. The 4-mg/kg (4-dose) regimen eliminated biolumi-
nescent activity throughout the duration of the study, and all mice 
survived to study discontinuation at day 212. Together, these stud-
ies showed potent in vivo activity of CD46-ADC. This effect is 
dose dependent, with significant activity at a very low dose (0.8 
mg/kg) (HR = 0.215 compared with control-ADC; P = 0.004) and 
apparent curative potential at a moderate dose of 4 mg/kg.
Establishing a clinical biomarker for CD46 expression in MM. 
The CD46 gene is located on 1q32, in proximity to a clinically 
used FISH probe at 1q21. We thus postulated that patients with 
amp1q21 may also amplify 1q32 and therefore carry increased 
CD46 expression. To explore this we mined data sets from previ-
ous gene expression analyses in MM (31–33). By Affymetrix array, 
CD46 transcript increased 3-fold in MM cells compared with nor-
mal plasma cells (P = 6.375 × 10–5) and 
was also significantly increased in a 
sequential manner between mono-
clonal gammopathy of unclear sig-
nificance (MGUS) and smoldering 
myeloma (asymptomatic proliferative 
plasma cell states) (Supplemental Fig-
ure 9, A–C). Furthermore, data anno-
tated by 1q21 FISH status (33) demon-
strated coamplification of CD46 by 
array comparative genomic hybrid-
ization (Supplemental Figure 9D) 
and a concomitant 2.8-fold increase 
in CD46 transcript expression (P = 
0.002) compared with MM samples 
that were 1q21 normal by FISH (Sup-
plemental Figure 9E).
Analysis of additional data 
derived from the CoMMpass Study 
(Interim Analysis 6) also confirms 
that about 30% of newly diagnosed 
patients demonstrate focal amplifi-
cation of the myeloid cell leukemia-1 
(MCL1) gene located at 1q21 (Figure 
5A). In addition to 1q21, the entire-
ty of the 1q arm is amplified for a 
similar fraction of patients (Figure 
5A, gray track). Furthermore, coam-
plification analysis for individual 
samples demonstrates that 85.4% of 
patients carrying MCL1 amplification 
also amplified CD46, and the major-
ity of the 1q arm (purple line). Thus, 
there is a high level of coamplifica-
tion between a negative prognostic 
factor (amp1q21) and the gene for 
the CD46-ADC target. Additional-
ly, comparison of the correlations of 
MCL1 with CD46 copy number and 
MCL1 with CKS1B (another gene 
located at 1q21) demonstrates that the 
1q21 and 1q32 loci correlate similarly 
(Figure 5B and Supplemental Figure 
10, A and B). Lack of correlation between CCND1 (chromosome 
11) copy number and CD46 or MCL1 indicates that coamplifica-
tion is unique to genes on the 1q arm (Supplemental Figure 10, 
C and D). Samples with copy gain on either CD46 or MCL1 also 
demonstrate significantly increased CD46 transcript expression, 
compared with samples not demonstrating copy gain at these loci 
and with the overall population (Figure 5C). Thus, data from both 
published studies and the CoMMpass Study indicate that nearly 
all patients with amp1q21 also demonstrate CD46 gene amplifica-
tion and increased CD46 mRNA expression.
Cell surface CD46 is increased in myeloma samples with gain of 
1q21 by FISH. To validate 1q21 FISH as a clinical biomarker, we next 
measured CD46 cell surface expression in a cohort of patients at 
diagnosis or at relapse with a pure monoclonal population of MM 
Figure 5. CD46 locus is frequently coamplified with 1q21, and copy gain for either MCL1 or CD46 identi-
fies patients with high CD46 expression. (A) About 30% of newly diagnosed patients demonstrate 1q21 
copy gain overlapping the MCL1 locus by array comparative genomic hybridization (CGH), defined as log2 
copy number >0.3, and a similar proportion demonstrate amplification along the 1q arm, including CD46 
(gray shaded histogram; left axis). High frequency of coamplification along the 1q arm with MCL1 ampli-
fication is shown by the purple line and quantified on the right axis (n = 322 patients). (B) Dot plot of log2 
CGH values in patient samples indicates that copy numbers for CD46 and MCL1 loci are highly correlated 
and cluster in regular copy number intervals (n = 322 patients). (C) Mean CD46 transcript expression values 
(quantified as fragments per kilobase per million mapped reads [FPKM]) for CD46 or MCL1 copy-amplified 
cohorts, defined by ≥0.3 log2 CGH value, versus nonamplified cohorts indicate high CD46 expression in 
MCL1 or CD46 amplified patient samples, compared with total population or samples without copy gain  
(n = 260 patients). Data represent mean ± 95% CI. One-way ANOVA with Tukey’s multiple comparison 
correction, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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cells (Supplemental Table 1). An initial cohort of 10 MM patient 
samples was evaluated, 7 of which had amp1q21 and 3 of which did 
not (Supplemental Table 1, samples 1–10). CD46 was coexpressed 
on the MM cell surface with well-known myeloma antigens CD38 
and CD138 (Figure 6A), but expressed at low levels on nonplasma 
cells (NPCs) that have negative/low CD38 and CD138 expression 
and represent a heterogeneous mixture of normal mononucle-
ar cells (MNCs) (Supplemental Figure 11, A and B). The average 
mean fluorescence intensity (MFI) (anti-CD46) of CD138-posi-
tive/CD38-positive cells by FACS was 152,049 (SEM 22,767) with 
amp1q21, significantly higher compared with 37,113 (SEM 9,926) 
in patients with normal 1q21 (P = 0.014, 2-tailed t test; Supplemen-
tal Figure 11C). Thus, CD46 was overexpressed on MM cells from 
all patients and further amplified in patients with amp1q21, with 
low expression on nonmalignant NPCs.
We next measured cell surface antigen density by FACS to 
quantify the expression difference between amp1q21 and nor-
mal 1q21 patients. Samples were analyzed for CD46 cell surface 
expression on MM cells and matching NPCs from patients with 
and without amp1q21. In a second cohort of 10 patients, unse-
lected MNCs were analyzed (Supplemental Table 1, samples 
11–20). In 5 patients with amp1q21 the mean CD46 antigen den-
sity on MM cells was 313,190 (SEM 68,849), and on NPCs was 
26,214 (SEM 6,329) (Figure 6B; 2-tailed t test, P = 0.0032). In 
5 patients with normal 1q21 the mean CD46 antigen density on 
MM cells was 121,316 (SEM 28,352), and on NPCs was 23,388 
(SEM 3,729) (Figure 6C; 2-tailed t test, P = 0.009). CD46 anti-
gen density was significantly higher on amp1q21 MM samples 
compared with MM with normal 1q (Figure 6D; 2-tailed t test, 
P = 0.032), supporting the hypothesis that CD46 cell surface 
expression variability in MM is due to selective genomic amplifi-
cation in patients with amp1q21.
We next sought to better differentiate the levels of CD46 on 
various nontumorigenic or normal hematopoietic cell popula-
tions. CD46 antigen density was measured on hematopoietic stem 
cells, progenitors, B cells, T cells, granulocytes, monocytes, mega-
karyocytes, and platelets (Supplemental Figure 12). In BM from 7 
subsequent patients with MM, granulocytes had the highest CD46 
antigen density (mean 39,248, SEM 6,492), but other nontumor 
cell populations all had low CD46 expression (antigen density 
range 11,593–23,764) (Figure 6E and Supplemental Table 2). In 
BM from normal donors, monocytes (mean 58,320, SEM 6,874) 
and granulocytes (mean 54,439, SEM 10,688) had the highest 
CD46 antigen density, whereas others again were relatively low 
(range 8,443–23,772) (Figure 6F and Supplemental Table 3). Simi-
lar results were obtained from peripheral blood (PB) samples from 
normal donors, showing that CD46 antigen density is highest on 
monocytes (mean 56,237, SEM 11,649) and granulocytes (mean 
40,523, SEM 8,165), but otherwise low (range 3,698–8,256) (Fig-
ure 6G and Supplemental Table 4).
In summary, CD46 expression was high on MM cells from 
100% of patients (n = 25, cumulatively) and further amplified in 
Figure 6. CD46 is overexpressed on cell surface of primary MM patient cells and further amplified in patients with amp1q21 compared with normal 1q. 
(A) FACS plot showing that CD46 surface expression correlates with CD38 in CD138-selected cells to identify the MM population by FACS (representative 
data, n = 25). (B) Quantitative FACS results for CD46 antigen density from MM versus NPCs from patients with normal (Nml) 1q (n = 5). (C) Quantitative 
FACS results for CD46 antigen density from MM versus NPCs from patients with amp1q21 (1q+, n = 5). (D) CD46 antigen density is further increased in 
amp1q21 patients (n = 5) compared with patients with normal 1q (n = 5). (E) CD46 antigen density on various BM normal cell populations compared with 
MM cells from 7 additional patients. (F) CD46 antigen density on various BM cell populations from 3 normal donors. (G) CD46 antigen density on various 
peripheral blood cell populations from 3 normal donors. Data represent mean ± SEM. Two-tailed t test, *P < 0.05, **P < 0.01.
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ited because of the narrow range 
of CD46-ADC potency observed, 
and the fact that all but 1 of the MM 
cell lines have 1q21 gain. However, 
in patient samples, ADC sensitiv-
ity ex vivo also suggests that 1q21 
FISH and antigen density may be 
potential biomarkers for response 
in MM patients.
We also evaluated ADC induc-
tion of apoptosis and death of 
CD138-positive and CD138-neg-
ative fractions by FACS. Gating 
specifically on CD38-positive, 
CD138-selected cells, FACS for 
annexin V and PI was performed 
after 48-hour treatment of MM 
patient cells ex vivo with grad-
ed concentrations CD46-ADC. 
Gating for viable annexin V–neg-
ative/PI-negative cells, MM cell 
killing at 48 hours was consistent 
with cell line proliferation assays 
at 96 hours, with EC50 less than 
10 nM (Supplemental Figure 13). 
No toxic effect on nonmalignant 
CD138-negative cells was observed 
up to 100 nM (Supplemental Fig-
ure 13). Overall, these data suggest 
that CD46-ADC will be selective-
ly cytotoxic to MM cells and may 
have improved potency in patients with amp1q21.
Tolerability evaluation of CD46-ADC in human CD46–express-
ing transgenic mice. We sought to study tolerability of CD46-ADC 
in vivo using a relevant animal model. The expression of murine 
CD46 is restricted to the inner acrosomal membrane of testes and 
the retina (34, 35). In addition, human CD46 and murine CD46 
share weak homology, and our anti-CD46 antibody does not bind 
the mouse CD46 protein. For these reasons, the mouse xenograft 
experiments shown above provide limited data on potential tox-
icity of CD46-ADC. To circumvent this limitation, we studied in 
vivo tolerability of CD46-ADC using human CD46 transgenic 
mice (36). Following a single i.v. bolus injection of 6 mg/kg CD46-
ADC, animals were monitored for body weight loss and sign of 
overt toxicity for 14 days. No significant body weight loss or overt 
sign of toxicity was observed (Figure 8A). At study discontinuation 
on day 14, necropsy study was performed. All organs appeared to 
be morphologically normal except for a slight increase in spleen 
size in CD46-ADC–treated animals. Histologic analysis of major 
organs showed no notable tissue damage (Figure 8B at ×20 and 
Supplemental Figure 14 at ×40 magnification). To assess whether 
CD46-ADC caused any notable effect on B cells in the spleen, we 
stained spleen sections with anti–mouse CD20 (Figure 8C). We 
measured diameters of CD20-positive regions in CD46-ADC– 
and control ADC–treated groups, and found no statistically signif-
icant difference (Figure 8D). Thus, in this relevant small-animal 
model, CD46-ADC appears to be tolerated in vivo.
patients with amp1q21. The overall CD46 expression on normal 
hematopoietic cells is low. Notably, monocytes and granulocytes 
expressed relatively higher levels of CD46 compared with other 
normal cell populations. Interestingly, benign plasma cells from 
normal donors also had low CD46 antigen density (mean 22,475, 
SEM 4,869; Figure 6F and Supplemental Table 3), suggesting that 
high CD46 on MM cells occurs with malignant transition.
Anti–CD46-ADC potently and selectively induces primary MM 
cell apoptosis and death. We first studied internalization of our 
anti-CD46 antibodies by primary MM cells. As shown in Figure 
7A (left panel), the anti-CD46 antibody was internalized and 
partially colocalized with LAMP1. In contrast, no internalization 
into CD138-negative MNCs was observed (Figure 7A, right). We 
next evaluated whether CD46-ADC was specifically cytotoxic to 
primary MM cells ex vivo. BM MNCs were treated with 0–100 
nM in triplicate for each condition and evaluated by FACS after 
48 hours. CD46-ADC treatment consistently reduced the num-
ber of MM cells, with no effect from nonbinding ADC control 
(Figure 7B). CD46-ADC had no effect on the number of NPCs in 
all patients tested (Figure 7C). Furthermore, the MM cells with 
gain of chromosome 1q21 showed higher sensitivity to CD46-
ADC (lower EC50) compared with patients with normal 1q21 
(Figure 7B). Notably, only weak correlation with known 1q21 
copy number and CD46-ADC potency was found in a limited 
number of myeloma cell lines for which information on both 
was available (Supplemental Figure 7C) (2). The analysis is lim-
Figure 7. Ex vivo evaluation of CD46-ADC in patient sample MM cells. (A) Internalization of CD46 antibody 
(red) into MM patient cells ex vivo. CD138 positively selected cells from a patient with MM were incubated with 
CD46 antibody for 18 hours and costained with anti-LAMP1 antibody (green) and Hoechst dye (blue). Rep-
resentative cell illustrates the intracellular localization of CD46 antibody, partially colocalizing with the late 
lysosomal marker LAMP1 (left). CD138-negative cells were treated in the same fashion and showed minimal 
binding of CD46 antibody without discernible internalization (right). Images were taken using a digital confocal 
microscope (FluoView, Olympus) at ×60 magnification. (B) CD46-ADC depletes the number of CD138-positive, 
CD38-positive MM cells more potently in patients with amp1q21. Mean values with SEM are shown for CD46-
ADC treatment of 2 patient samples with amp1q21 (red lines) and 2 patient samples with normal 1q21 (blue 
lines), compared with cells treated with nonbinding control ADC (black). (C) CD46-ADC does not affect the 
number of NPCs up to a concentration of 100 nM (n = 4) (data represent mean ± SEM).
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expression level increases in the presence of a model of the BM 
microenvironment. Previous studies have characterized the CD46 
gene as a transcriptional target of signal transducer and activator 
of transcription 3 (STAT3) (37). This finding is consistent with the 
notion that exposure of MM cells to marrow-derived cytokines, 
commonly associated with the activation of STAT3 activity, results 
in subsequent induction of CD46 transcript expression.
CD46 is an attractive cell surface target for ADC development 
because of its original identification from an unbiased screen-
Discussion
MM is incurable, and patients inevitably develop resistance to 
current therapies. New molecular targets and targeting agents 
have the potential to overcome limitations associated with current 
therapeutic strategies. Our study shows that CD46 is an attractive 
novel target for development of antibody therapy against MM. We 
have shown that CD46 is highly expressed on the surface of MM 
cell lines and primary MM cells (with relatively low expression 
on various normal BM and PB cell populations). In addition, the 
Figure 8. Evaluation of tolerability of CD46-ADC in transgenic mice expressing human CD46. Three mice were treated with CD46-ADC or isotype (nonbind-
ing) control ADC at 6 mg/kg i.v. and monitored for 14 days. (A) Body weight analysis over the monitoring period showed no weight loss greater than 12% 
following CD46-ADC injection. (B) Histological analysis at the time of experiment discontinuation. Images were taken by a Keyence digital microscope at ×20 
magnification. Histological features (arrows) are indicated on the images. No notable difference was observed between CD46-ADC– and control ADC–treated 
samples. Scale bars: 100 μm. (C) Immunohistochemistry analysis of CD20-positive region in CD46-ADC– and control ADC–treated spleens. Scale bars: 100 
μm. (D) Diameters of CD20-positive regions in CD46-ADC– and control ADC–treated spleens (n = 74 for CD46-ADC–treated and 81 for control ADC–treated, 
respectively). No significant difference was observed (2-tailed t test, P > 0.05).
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has a known role in negative regulation of complement, rendering 
cells dependent on its expression (14). In addition, the genomic 
region where CD46 resides is amplified in R/R MM (2, 21). This 
FISH biomarker for CD46 amplification is thus far unique in MM. 
Finally, the internalization mechanism of other MM antigens has 
not been characterized to assess whether they are optimally suited 
for ADC development (11). On the other hand, we have shown that 
our anti-CD46 antibodies enter cells through macropinocytosis 
(Y. Su and B. Liu, unpublished observations), an inherently tumor- 
selective pathway (23, 24), and our CD46-ADC showed high 
potency against MM cells, but selectively spared normal BM cells.
Interestingly, CD46 has been independently targeted for 
MM and other malignancies using oncolytic measles virus (17). 
An early report of 2 patients treated in phase I study in myeloma 
described substantial decreases in disease activity (47). It would 
be of interest to evaluate whether patients who tend to respond 
have amp1q21, as would be suggested by our study finding of 
higher CD46 expression levels in these patients. While promising, 
the approach needs to address immunogenicity of measles virus 
that limits repeat dosing. Human antibody-based approaches 
such as our CD46-ADC have less potential for immunogenicity. 
Nonetheless, the oncolytic measles virus approach has shown that 
CD46-targeted therapy can lead to tumor-specific effects (47, 48). 
Other than infusion-related reactions, oncolytic measles virus 
was well tolerated, showing that CD46 can be engaged in humans 
without triggering unacceptable toxicity (47, 48). It remains to be 
tested whether our CD46-ADC is safe in phase I trials.
We have found thus far that CD46-ADC was tolerable in mice, 
including transgenic mice that express the human CD46 gene. 
Our ex vivo study of CD46-ADC on primary cells showed potent 
cytotoxicity on myeloma cells, but not NPCs. Further study will 
determine potential differential effects of the ADC on subpopu-
lations of NPCs. Because CD46 is expressed at low levels on all 
nucleated cells, there is potential for a tissue sink that could also 
impact the pharmacokinetics of CD46-ADC. We acknowledge 
this potential problem but believe it will be a minor issue as our 
quantitative measurement has shown that the CD46 antigen den-
sity on NPC subpopulations is low (typically ≤25,000 per cell). 
Ultimately, the pharmacokinetics and toxicity of CD46-ADC need 
to be investigated in nonhuman primates.
Mutations in CD46 are known to be a predisposing factor for 
about 10% of cases of atypical hemolytic uremic syndrome, with 
incomplete penetrance (49). CD46 expression is low on most nor-
mal cells, including endothelial cells (14, 50). A potential toxicity 
concern is that an antibody-based therapy targeting CD46 may 
block complement inhibition and potentially induce atypical hemo-
lytic uremic syndrome. However, our ADC binds a conformational 
epitope residing in Sushi domains 1 and 2, outside of the interface 
where the complement pathway components bind (51). Consistent 
with this, we have observed that our CD46 antibody does not com-
pete with complement binding and does not enhance complement 
activity in in vitro assays (Y. Su and B. Liu, unpublished observa-
tions). Therefore the ADC is not expected to lead to excessive ter-
minal complement cascade activation on normal cells.
In addition to MM, CD46 is overexpressed in prostate cancer, 
ovarian cancer, cervical cancer, breast cancer, endometrial cancer, 
lung cancer, and leukemia (38, 52, 53). Intriguingly, 1q gain is also 
ing strategy that prioritized macropinocytosing antigens in their 
native conformations (12, 23). Our novel CD46-ADC potently and 
selectively eliminates MM cell lines in vitro and in vivo, and pri-
mary MM cells ex vivo. A unique distinction of CD46 is that the 
gene is located near a FISH probe already in routine clinical use 
(1). This 1q21 probe frequently undergoes genomic gain in patients 
with MM, especially in high-risk and R/R disease (2, 21). We have 
found that the genomic gain correlates well with CD46 antigen 
expression level and susceptibility to CD46-ADC. The discovery 
of a readily obtainable biomarker for target overexpression can 
prove extremely valuable for patient selection and stratification in 
clinical trials. Overall, our data suggest potential for CD46-ADC 
as a novel therapeutic for MM, with particular benefit predicted 
for patients with genomic amplification of the region where the 
CD46 gene resides (1q).
The finding of a putative drug target in high-risk or R/R MM 
with amp1q21 could be highly advantageous for the treatment 
of advanced disease. Putative oncogenes located on 1q include 
CKS1B and MCL1. In addition, CD46 overexpression itself is 
protective for cancer cell evasion of complement activation (38). 
MCL-1 is a prosurvival member of the B cell lymphoma 2 (BCL-2) 
family that is also overexpressed in high-risk MM patients and 
those with relapsed disease (39, 40). Importantly, MCL-1 upreg-
ulation has been described to evoke bortezomib resistance, which 
adds significant difficulty in treating advanced myeloma (41–43). 
These features of MM cells with 1q21 gain make CD46 an attrac-
tive target to combat drug resistance and oncogene accumulation 
in advanced disease.
If successful, there are several myeloma disease settings that 
may benefit from treatment with an efficacious ADC: (a) R/R MM 
with resistance to IMiDs and proteasome inhibitors, for which 
there is great clinical need for new therapies; (b) patients with 
high-risk disease features that tend to progress rapidly through 
current therapies — patients with amp1q21 at diagnosis fit into this 
category (2), making a particularly attractive group for treatment 
with CD46-ADC; and (c) addition of CD46-ADC to standard 
induction regimens for patients with newly diagnosed MM, with 
or without subsequent autologous stem cell transplant. Although 
standard approaches often achieve deep remission, they are not 
curative treatment for MM. The addition of a targeted cytotoxic 
therapy, such as an ADC that has a different mechanism of action, 
could potentially improve the odds of attaining cures that have 
thus far been elusive.
Current efforts on antibody targeting against MM are focused 
on a few lineage markers such as CD138 and CD38. Currently, 3 
ADCs have been developed and entered clinical trials for MM. 
These include the anti-CD138 ADC indatuximab ravtansine (may-
tansinoid toxin DM4, disulfide cleavable linker), the anti-CD56 
ADC lorvotuzumab mertansine (maytansinoid toxin DM1), and 
the anti-BCMA ADC GSK2857916 (MMAF toxin) (44–46). The 
linker/toxin combination used by CD46-ADC is most similar to 
the anti-BCMA ADC, except that the linker used is cleavable. The 
linker/toxin combination for CD46-ADC is not used by any ADCs 
currently in clinical trials, but has been described previously (29). 
A key differentiation between CD46 and the other targets of ADCs 
in clinical trials for myeloma is that CD46 is a functional antigen 
and its expression is increased as the disease progresses. CD46 
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tem (ForteBio) with the biosensor coated with the 23AG2 antibody. 
Affinity for living myeloma cells was measured by FACS on RPMI8226 
and MM1.S cell lines with MFI values curve-fit using 1-site specific 
binding model (GraphPad). A control IgG1 (YSC10) was created from 
a phage antibody picked randomly from the nonselected library, which 
does not bind to any cell surface antigen and hence is designated as a 
nonbinding antibody in this article.
MM cell lines. MM cell lines bearing the firefly luciferase reporter 
gene were provided by Constantine Mitsiades (Dana-Farber Can-
cer Institute, Boston, Massachusetts, USA) (56). RPMI8226, MM1.S, 
and MM1.R were purchased from American Type Culture Collection 
(ATCC). All MM cell lines were maintained in RPMI1640 with 100 U/
ml penicillin, 100 μg/ml streptomycin, and 10% FBS. INA-6 was sup-
plemented with IL-6 (2 ng/ml). Patient stromal culture, BM61, was 
derived from CD138-negative MNC fractions derived from BM aspirate.
FACS analysis of cell surface CD46 expression. To determine CD46 
expression on MM cells, FACS was performed using biotin-labeled 
human anti-CD46 IgG1 followed by detection with Alexa Fluor 647–
conjugated streptavidin (Life Technologies). All samples were ana-
lyzed using an Accuri C6 (BD Biosciences) with a 96-well autosam-
pler. Nonspecific Fc receptor binding was minimized by preincubation 
with Clear Back reagent (Medical and Biological Laboratories Co.). To 
determine CD46 expression on patient samples, multicolor analysis 
was performed using FITC-conjugated anti-CD38 antibody (clone 
AT1, Stem Cell Technologies) to identify MM cells in CD138-selected 
samples. For FACS of CD46 on various BM and PB cell populations, an 
extended antibody panel was used with anti-CD38 (clone HIT2) Per-
CP-Cy5.5, anti-CD138 (clone MI15) BV421, anti-CD45 (clone HI30) 
BV510, anti-CD19 (clone HIB19) BB515, anti-CD4 (clone RPA-T4) 
PerCP-Cy5.5, anti-CD8 (clone RPA-T8) Pacific Blue, anti-CD3 (clone 
HIT3a) FITC, anti-Lineage FITC, anti-CD34 (clone 581) PE, anti-
CD61 (clone VI-PL2) PE, anti-CD33 (clone HIM3-4) FITC, anti-CD14 
(clone Hop9) PerCP-Cy5.5 (BD Biosciences), and Live/Dead-Near IR 
(Life Technologies/Thermo Fisher Scientific) on a FACSCanto II (BD 
Biosciences) flow cytometer.
Cell surface antigen density determination. Quantitative flow 
cytometry was performed to determine CD46 antigen density. Anti-
CD46 and anti-CD38 antibodies were labeled with Alexa Fluor 647 
(Molecular Probes/Life Technologies) according to the manufactur-
er’s recommendations. MFI conversion to molecules of equivalent sol-
uble fluorophores (MESF) was done by generation of a standard curve 
with Quantum beads (Bangs Laboratories) (25). The fluorophore-to- 
antibody ratio of the labeled antibodies was determined using Simply 
Cellular anti-human (for CD46) or anti-mouse (for CD38) IgG beads 
(Bangs Laboratories). Finally, conversion of MESF to cell surface anti-
gen density was done by division of the fluorophore-to-antibody ratio.
Antigen shedding. To assay for CD46 antigen shed into cell culture 
media, 4 × 105 RPMI8226 cells were seeded in a 6-well plate (Falcon) 
and cultured in a CO2 incubator at 37°C overnight. Next, 5 ml serum-
free culture medium containing 10 μg/ml anti-CD46 antibody or non-
binding control antibody was added for an additional 24-hour incuba-
tion. The cells were separated by centrifugation at 491 g for 10 minutes, 
and lysed with cell lysis buffer (20 mM Tris-HCl, pH 7.4, 0.3 M NaCl, 
1% NP-40) supplemented with complete protease inhibitor cocktail 
(Roche). The supernatants were concentrated 50 times by centrifug-
ing in a Centricon filter unit (Millipore) at 3,488 g for 30 minutes at 
4°C. Samples were boiled in SDS sample buffer and analyzed by SDS-
common in cancers from multiple tissue types (54, 55). We spec-
ulate that 1q gain may be the mechanism for CD46 upregulation 
in other cancers. Thus, CD46-ADC may have efficacy in other 
malignancies, particularly those that commonly have copy num-
ber gain of 1q.
In conclusion, we have identified a novel functional antigen, 
CD46, for ADC targeting of MM, with unique potential for high-
risk and R/R disease that has genomic amplification at the CD46 
gene locus and is in dire need of therapy. We have developed a 
novel CD46-ADC and shown that it is highly potent and selec-
tive in eliminating MM cells (cell lines and primary tumor cells) 
in preclinical models. We have found that CD46 genomic gain on 
chromosome 1q correlates with antigen amplification, and further 
identified a biomarker based on a clinical FISH test that can be 
used for patient stratification. Thus, our study could lead directly 
to the application of a novel ADC therapeutic for treating MM.
Methods
MM patient and normal donor samples. BM samples from MM patient 
samples 1–10 were separated into 2 fractions based on selection for 
CD138 expression with EasySep magnetic bead columns (Stem Cell 
Technologies). Primary cells were cultured in RPMI1640 media 
with 100 U/ml penicillin, 100 μg/ml streptomycin, 10% FBS, and 
2 ng/ml IL-6. BM and PB controls from normal donors were pur-
chased from AllCells.
Antibody generation. We have previously identified a phage anti-
body binding to tumor cells in situ by laser capture microdissection–
based selection using prostate cancer specimens (12). We later iden-
tified that CD46 is the target antigen and the original antibody binds 
to a conformational epitope residing in Sushi domains 1 and 2 (Y. Su 
and B. Liu, unpublished observations). A combined phage and yeast 
antibody display library selection approach (28) was used to identify 
additional anti-CD46 human antibodies. Briefly, the human CD46 
gene fragment containing domains 1 and 2 was cloned into the pFUSE-
Fc vector (Invivogen) to create a recombinant Fc fusion molecule that 
was produced in HEK293a cells, and purified by protein A affinity 
chromatography. A nonimmune phage antibody display library con-
taining 1 billion members (Y. Su and B. Liu, unpublished observations) 
was incubated with CD46-Fc fusion coated on polystyrene beads in 
PBS/2% dry milk at room temperature for 1 hour, followed by wash-
ing 3 times with PBS/2% dry milk, elution with 100 mM triethyl-
amine, and neutralization with 1 M Tris-HCl, pH 6.8. After 3 rounds of 
selection, binding phages were screened by FACS on Du145 cells and 
sequenced. Unique phage antibodies were retested on recombinant 
CD46-Fc fusion–coated microtiter plates to confirm binding speci-
ficity. In parallel, an alternative strategy was used selecting the phage 
antibody library on live tumor cells, followed by transfer of the out-
put into a yeast surface display vector, and then FACS-based selection 
using low-concentration ligands to enrich high-affinity binders to the 
recombinant CD46-Fc fusion protein as previously described (28). A 
panel of novel anti-CD46 antibodies was identified and further stud-
ied for internalization and macropinocytosing activities (23), and the 
23AG2 lead antibody was chosen for ADC development. Full-length 
human 23AG2 IgG1 was constructed from phage antibody sequence, 
produced in HEK293a, and purified by protein A chromatography 
as previously described (23). Affinity of 23AG2 IgG1 to recombinant 
CD46-Fc (domains 1 and 2) was measured by the label-free BLItz sys-
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staining were gated separately for the CD138-positive, CD38-positive 
MM cells and the CD138-negative, CD38-negative NPCs.
Cell proliferation assays. The firefly luciferase reporter–expressing 
lines were used to determine ADC potency in vitro. Cells were plated 
into 96-well plates at 2,000 per well and incubated for 96 hours with 
CD46-ADC. Following administration of luciferin, firefly luciferase 
activity was measured as an indicator of viability using a BioTek Syn-
ergy 2. The data were normalized against untreated control wells and 
EC50 estimated using GraphPad Prism version 6.0c.
For assessment of patient cell sensitivity to ADC, unselected MNC 
samples were plated at 4 × 104 cells per well in 96-well plates and treat-
ed with CD46-ADC or nonbinding ADC at 37°C for 48 hours. Cells 
were harvested after treatment, washed, and stained with phycoeryth-
rin-conjugated anti-CD138 (BD Biosciences) and FITC-conjugated 
anti-CD38 antibodies. The numbers of CD138-positive, CD38-posi-
tive MM cells and CD138-negative, CD38-negative NPCs were gated 
and counted, with the curve constructed following normalization to 
the cell numbers in untreated wells. Treatments were performed in 
triplicate and plotted with SEM.
BM stromal cell coculture and conditioned media. BM coculture exper-
iments evaluating ADC activity in MM1.S cells were performed using 
compartment-specific bioluminescence as previously described (56). 
Following ammonium-chloride-potassium lysis, CD138-positive cells 
were isolated from MNCs using the EasySep Human Whole Blood and 
BM CD138 Positive Selection Kit (Stem Cell Technologies). HS5 and 
HS27A were purchased from ATCC. BM61 cells were generated from 
culture of CD138-negative BM MNCs from a myeloma patient sample. 
HS5, HS27A, or BM61 cells were grown in RPMI1640-supported cul-
tures for later use in monoculture or coculture assays. Coculture assays 
were initiated using a 2:1 ratio of bone marrow stromal cells to MM cells.
CD46 gene expression of MM cells in coculture was evaluated as 
follows: MM1.S cells were seeded in monoculture at a density of 5 × 105 
cells/ml, or, for coculture, seeded at the same density over 70% con-
fluent stromal cells. After 24 hours, cells were collected and treated 
with trypsin-free dissociation solution (Accumax), and CD138+ mag-
netic bead separation (Miltenyi) was used to isolate MM1.S cells. FACS 
for mCherry expression verified <5% contamination by stromal cells 
(that do not carry the mCherry gene). mRNA-Seq was performed on 
MM1.S cells as previously described (57), and sequenced on an Illu-
mina HiSeq 2500. Normalized sequencing reads, in fragments per 
kilobase per million mapped reads (FPKM), mapping to CD46 canon-
ical transcript sequence were measured. A genome-wide sequencing 
data set from this experiment will be published separately (A. Wiita 
and B.T. Aftab, unpublished observations).
BM stromal cell–conditioned medium was collected from HS5 
cells cultured under serum-free conditions for 48 hours, as previously 
described (58). MM1.S and MM1.R cell CD46 and CD38 antigen den-
sity was measured with or without the addition of conditioned media 
for 72 hours.
CD46 knockdown. CD46 was targeted for knockdown with shRNA 
oligo with sequence 5′-ATTGGAGAGAGCACGATTTAT-3′. The shRNA 
sequence was cloned into pLKO.1-GFP vector, containing a U6 promot-
er to drive shRNA expression and an IRES-GFP as previously described 
(59). Lentivirus particles were produced in HEK293T cells by cotrans-
fection of shRNA constructs with pPax2 and pMD2.G. H929 MM cell 
lines were incubated with lentivirus and assessed for infection by GFP 
expression and CD46 knockdown by FACS 7 days after infection.
PAGE. After semi-dry transfer to Immobilon-P membrane (Millipore), 
Western blotting was performed using anti-CD46 antibody H-294 (sc-
9098, Santa Cruz Biotechnology) followed by anti-rabbit HRP (Jackson 
ImmunoResearch Laboratories) and detected by chemiluminescence 
with Pierce ECL Western Blotting Substrate (Pierce/Thermo Fisher 
Scientific) according to the manufacturer’s instructions. Images were 
captured using a C-DiGit blot scanner (LI-COR Biosciences).
Antibody internalization by confocal microscopy. Alexa Fluor 647–
labeled anti-CD46 antibody was incubated with MM cell lines for 4 
or 18 hours, washed with PBS, fixed with 4% PFA, permeabilized with 
PBS with 0.1% Triton X-100 and 1% BSA, and analyzed by confocal 
microscopy (Olympus FluoView). Nonbinding isotype antibody was 
studied in parallel as a control. For internalization by patient cells ex 
vivo, CD138-positive and CD138-negative (control) cells were incu-
bated with Alexa Fluor 647–labeled anti-CD46 or nonbinding isotype 
control antibodies for 18 hours, processed, and analyzed as described 
above. Subcellular localization to lysosomes was assessed by costain-
ing with LAMP1 antibody (clone D2D11, Cell Signaling Technology).
ADC generation and characterization. MMAF was conjugated to 
anti-CD46 IgG1 via an mcvcpab linker (29). To create the mcvcpab 
linker, N-ε-maleimidocaproyloxysuccinimide ester (Pierce) was dis-
solved in anhydrous dimethylformamide (DMF) (final 0.14 mM). 
This solution was then added to valine-citrulline-p-aminobenzylal-
cohol (Concortis Biosystems) (final 0.14 mM). After brief agitation 
to dissolve all components, diisopropylethylamine (DIPEA) was 
added (final 0.41 mmol), incubated at room temperature for 1 hour, 
and precipitated with cold ethyl acetate (EtOAc) to form mcvcpab. 
Bis-nitrophenyl carbonate (0.41 mmol) was added along with DIPEA 
(0.41 mmol) to mcvcpab dissolved in DMF and incubated at room 
temperature for 4 hours followed by EtOAc precipitation as before 
to yield maleimidocaproyl-valine-citrulline-p-aminobenzylalcohol 
p-nitrophenol carbonate (mcvcpab-PNP). MMAF hydrochloride salt 
(Concortis Biosystems), N-hydroxysuccinimide, and DIPEA were 
added to DMF-dissolved mcvcpab-PNP and incubated at room tem-
perature for 16 hours to form mcvcpabMMAF (29). CD46 IgG1 was 
reduced by tris(2-carboxyethyl)phosphine (TCEP) at 37°C for 2 hours, 
purified by Zeba spin column (Pierce/Thermo Fisher Scientific), 
buffer-exchanged into PBS with 5 mM EDTA, and incubated with 
linker-conjugated MMAF (mcvcpabMMAF) at room temperature for 
1 hour. Conjugation products were purified by running twice though 
the spin column to remove free MMAF and analyzed by HPLC using 
hydrophobic interaction chromatography with Infinity 1220 LC Sys-
tem (Agilent). The drug-to-antibody ratio is estimated from area inte-
gration using OpenLab CDS software (Agilent).
Apoptosis assay. Induction of apoptosis and cell death in myelo-
ma cell lines was evaluated using an annexin V–FITC Early Apoptosis 
Detection Kit (Cell Signaling Technology). Cell lines were seeded into 
96-well plates at 4 × 104 cells per well and incubated with varying con-
centrations of CD46-ADC or nonbinding control ADC at 37°C for 48 
hours. Apoptosis and cell death were assessed in triplicate by FACS for 
annexin V–FITC and PI. For primary samples, induction of apoptosis 
and cell death was also studied using the above approach, with the fol-
lowing modifications. Magnetic bead column-separated CD138-pos-
itive and -negative cell fractions were each plated at 4 × 104 cells per 
well and incubated with CD46-ADC or nonbinding ADC at 37°C. After 
48 hours, cells were analyzed by FACS using annexin V–FITC, PI, and 
CD38 (AT1, Santa Cruz Biotechnology). Annexin V staining and PI 
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hematologic malignancies tissue banks with approval from the UCSF 
and Western Institutional Review Boards, respectively. Informed con-
sent was obtained from all who donated samples. Identifying patient 
information was replaced with sequentially assigned numbers, in 
accordance with Health Insurance Portability and Accountability Act 
guidelines. Mouse studies were approved by the UCSF Animal Care 
and Use Committee (AN092211-01) and Washington University in St. 
Louis Animal Studies Committee (20100272A1).
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In vivo animal study. For in vivo efficacy assessment of CD46-
ADC, 5 × 105 RPIM8226-Luc or MM1.S-Luc cells were injected i.v. into 
NSG mice (4–6 weeks of age, male and female) (Jackson Laboratory) to 
create orthometastatic MM xenograft models. Bioluminescence imag-
ing (BLI) was used to monitor graft status (typically injected tumor cells 
established themselves in the BM and joint in 10 days). Four mouse 
groups were treated with CD46-ADC, control ADC (MMAF-conju-
gated to a nonbinding human IgG1), naked anti-CD46 antibody, or 
vehicle control (PBS). Tumor status was assessed by BLI and results 
analyzed by Living Image (PerkinElmer). After treatment, mice were 
continuously monitored for survival endpoints over a period of at least 
200 days. HR was determined by log-rank method and significance by 
Wilcoxon test. For tolerability assessment, transgenic mice expressing 
human CD46 under its native promoter (MCP) (36) were used (creat-
ed in strain C57BL/6, backcrossed into C57BL/6 background for over 
8 generations). The following primers were used for genetic screen-
ing: hMCPTg1 (5′-ATTGTTGCGTCCCATATCT-3′) and hMCPTg2 
(5′-CGGAGAAGGAGTACAGC-3′). Eight-week-old male mice were 
used in the study. Both the CD46-ADC and the YSC10 nonbinding 
control ADC were tested. Animals were injected with an i.v. bolus of 
the testing agent at 6 mg/kg (n = 3) and monitored for body weight loss 
and other overt signs of stress for 14 days. At the end of the experiment, 
major organs were harvested, formalin-fixed, frozen in liquid nitrogen, 
cryosectioned by Cryostat (Leica Biosystems), and stained with H&E 
(ScyTek Laboratories). To assess the status of CD20-positive region in 
the spleen, we stained the spleen sections with goat anti–mouse CD20 
antibody (clone M-20, Santa Cruz Biotechnology), and measured 
diameters of the CD20-positive regions following treatment (n = 74 for 
CD46-ADC–treated and 81 for control ADC–treated regions, respec-
tively). P value was calculated by 2-tailed Student’s t test.
Data mining. CD46 mRNA expression and copy number data were 
mined from 3 published data sets (31–33). Data from the CoMMpass Study 
(Interim Analysis 6) were provided by the Multiple Myeloma Research 
Foundation (https://research.themmrf.org). A detailed explanation for 
these data mining procedures is provided in the Supplemental Methods.
Statistics. All data are presented as mean and SEM unless noted. 
Significance was determined using GraphPad Prism version 6.0c. Two-
tailed Student’s t test was used for comparing 2 means. For comparing 
multiple groups, ANOVA was used with multiple comparison correc-
tion. Levels of significance are categorized as *P < 0.05, **P < 0.01, 
***P < 0.001, and ****P < 0.0001. Mouse model sample sizes were 
determined by preliminary in vivo experience with CD46-ADC and 
other ADCs published in the literature, rather than power calculation 
(46), and statistically significant results were observed.
Study approval. BM samples from MM patients were obtained 
from the UCSF and University of Colorado Anschutz Medical Campus 
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